Clinical trials have demonstrated that inhibiting this system would reduce the risk of coronary events.[4,5] RAAS is involved in many diseases, including atrial fibrillation, congestive heart failure, myocardial fibrosis, cardiomyopathy, hypertension, and type 2 diabetes mellitus.[6–10] Angiotensinogen (AGT) plays a crucial role in RAAS. This evidence concerns the gene AGT and type 2 diabetes mellitus.